296 related articles for article (PubMed ID: 34648141)
1. Haploinsufficiency, Dominant Negative, and Gain-of-Function Mechanisms in Epilepsy: Matching Therapeutic Approach to the Pathophysiology.
Carvill GL; Matheny T; Hesselberth J; Demarest S
Neurotherapeutics; 2021 Jul; 18(3):1500-1514. PubMed ID: 34648141
[TBL] [Abstract][Full Text] [Related]
2. Gene Editing and Modulation: the Holy Grail for the Genetic Epilepsies?
Carpenter JC; Lignani G
Neurotherapeutics; 2021 Jul; 18(3):1515-1523. PubMed ID: 34235638
[TBL] [Abstract][Full Text] [Related]
3. From molecules to medicines: the dawn of targeted therapies for genetic epilepsies.
Demarest ST; Brooks-Kayal A
Nat Rev Neurol; 2018 Dec; 14(12):735-745. PubMed ID: 30448857
[TBL] [Abstract][Full Text] [Related]
4. Dravet Syndrome: Novel Approaches for the Most Common Genetic Epilepsy.
Isom LL; Knupp KG
Neurotherapeutics; 2021 Jul; 18(3):1524-1534. PubMed ID: 34378168
[TBL] [Abstract][Full Text] [Related]
5. Allele-specific genome targeting in the development of precision medicine.
Wu J; Tang B; Tang Y
Theranostics; 2020; 10(7):3118-3137. PubMed ID: 32194858
[TBL] [Abstract][Full Text] [Related]
6. Precision Medicine in Epilepsy-The Way Forward?
Abbott CM
ACS Chem Neurosci; 2019 Apr; 10(4):2080-2081. PubMed ID: 30991807
[No Abstract] [Full Text] [Related]
7. Recent advances in epilepsy genetics.
Orsini A; Zara F; Striano P
Neurosci Lett; 2018 Feb; 667():4-9. PubMed ID: 28499889
[TBL] [Abstract][Full Text] [Related]
8. Identifying mutations in epilepsy genes: Impact on treatment selection.
Perucca P; Perucca E
Epilepsy Res; 2019 May; 152():18-30. PubMed ID: 30870728
[TBL] [Abstract][Full Text] [Related]
9. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
10. Monogenic Epilepsies: Disease Mechanisms, Clinical Phenotypes, and Targeted Therapies.
Guerrini R; Balestrini S; Wirrell EC; Walker MC
Neurology; 2021 Oct; 97(17):817-831. PubMed ID: 34493617
[TBL] [Abstract][Full Text] [Related]
11. Genome Editing as a Treatment for the Most Prevalent Causative Genes of Autosomal Dominant Retinitis Pigmentosa.
Diakatou M; Manes G; Bocquet B; Meunier I; Kalatzis V
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126147
[No Abstract] [Full Text] [Related]
12. From Genetic Testing to Precision Medicine in Epilepsy.
Striano P; Minassian BA
Neurotherapeutics; 2020 Apr; 17(2):609-615. PubMed ID: 31981099
[TBL] [Abstract][Full Text] [Related]
13. Clinical Trial Design for Disease-Modifying Therapies for Genetic Epilepsies.
Brock DC; Demarest S; Benke TA
Neurotherapeutics; 2021 Jul; 18(3):1445-1457. PubMed ID: 34595733
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Cas13a system: a novel approach to precision oncology.
Zhang J; You Y
Cancer Biol Med; 2020 Feb; 17(1):6-8. PubMed ID: 32296572
[No Abstract] [Full Text] [Related]
15. Personalized medicine in genetic epilepsies - possibilities, challenges, and new frontiers.
Helbig I; Ellis CA
Neuropharmacology; 2020 Aug; 172():107970. PubMed ID: 32413583
[TBL] [Abstract][Full Text] [Related]
16. Nucleic acid therapeutics in neurodevelopmental disease.
Winkelsas AM; Fischbeck KH
Curr Opin Genet Dev; 2020 Dec; 65():112-116. PubMed ID: 32623324
[TBL] [Abstract][Full Text] [Related]
17. Advances in the delivery of RNA therapeutics: from concept to clinical reality.
Kaczmarek JC; Kowalski PS; Anderson DG
Genome Med; 2017 Jun; 9(1):60. PubMed ID: 28655327
[TBL] [Abstract][Full Text] [Related]
18. Gene Editing and Gene-Based Therapeutics for Cardiomyopathies.
Ohiri JC; McNally EM
Heart Fail Clin; 2018 Apr; 14(2):179-188. PubMed ID: 29525646
[TBL] [Abstract][Full Text] [Related]
19. Clinical, biochemical, and molecular studies in pyridoxine-dependent epilepsy. Antisense therapy as possible new therapeutic option.
Pérez B; Gutiérrez-Solana LG; Verdú A; Merinero B; Yuste-Checa P; Ruiz-Sala P; Calvo R; Jalan A; Marín LL; Campos O; Ruiz MÁ; San Miguel M; Vázquez M; Castro M; Ferrer I; Navarrete R; Desviat LR; Lapunzina P; Ugarte M; Pérez-Cerdá C
Epilepsia; 2013 Feb; 54(2):239-48. PubMed ID: 23350806
[TBL] [Abstract][Full Text] [Related]
20. Differential molecular and behavioural alterations in mouse models of GABRG2 haploinsufficiency versus dominant negative mutations associated with human epilepsy.
Warner TA; Shen W; Huang X; Liu Z; Macdonald RL; Kang JQ
Hum Mol Genet; 2016 Aug; 25(15):3192-3207. PubMed ID: 27340224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
